← Leaderboards
Anderson Gaweco
Innovimmune Biotherapeutics, Inc.
$3,587,701
Attributed
$3,587,701
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $995.9K · FY2011–16$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,587,701 · 2
By mechanism
R44$2,987,701 · 1
R43$600,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Disease Model”
- Richard A Gibbs · Baylor College Of Medicine$159,491,891
- Michael W Weiner · Northern California Institute Res &Educ$150,464,353
- Garret A Fitzgerald · University Of Pennsylvania$124,179,279
- Randall J Bateman · Washington University$123,602,970
- Joseph E Robertson · Oregon Health & Science University$121,731,359
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
Research focus
Disease ModelDesignCd4 Positive T LymphocytesCxcr4 GeneComplexCytokineCatalytic DomainCandidate SelectionCost EffectiveCostCellsClinical ResearchCommercializationCxcr4 ReceptorsAnalogAutoimmune DiseasesBaseAdultAffinityBiological ProcessBinding SitesComputer SimulationAgreementDisease Progression
Grant awards (6)
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$995,900
R44 · FY2016 · AI · contact PI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$995,900
R44 · FY2015 · AI · contact PI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$995,900
R44 · FY2014 · AI · contact PI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis$1
R44 · FY2014 · AI · contact PI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis Treatment$300,000
R43 · FY2012 · AI · contact PI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis Treatment$300,000
R43 · FY2011 · AI · contact PI